Quirk Gerald E 4
4 · Syros Pharmaceuticals, Inc. · Filed Feb 21, 2018
Insider Transaction Report
Form 4
Quirk Gerald E
Chief Legal Officer
Transactions
- Award
Stock Option (right to buy)
2018-02-16+75,000→ 75,000 totalExercise: $10.09Exp: 2028-02-15→ Common Stock (75,000 underlying) - Award
Stock Option (right to buy)
2018-02-16+11,666→ 11,666 totalExercise: $13.30From: 2018-02-16Exp: 2026-09-26→ Common Stock (11,666 underlying)
Footnotes (2)
- [F1]This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.
- [F2]On September 27, 2016, the Reporting Person was granted an option to purchase 35,000 shares of common stock. The option vests upon the achievement of performance-based criteria as determined by the Issuer's Board of Directors. On February 16, 2018, it was determined that certain of the performance criteria were met, resulting in vesting of the option as to 11,666 shares.